Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.54%
#4 aPriori aPriori +175.89%
#5 Bedrock Bedrock +77.61%
#6 Cysic Cysic +53.64%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.87%
#9 Bitway Bitway +28.74%
#10 COTI COTI +27.09%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Synovics Pharmaceuticals, Inc. Synovics Pharmaceuticals, Inc.

Synovics Pharmaceuticals, Inc.

SYVC
Rank in Stocks #42246
Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the... Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company’s OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.98K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Synovics Pharmaceuticals, Inc. (SYVC)

Category

Healthcare
Revenue for Synovics Pharmaceuticals, Inc. (SYVC)
Revenue in Aug 2026 TTM: 0
According to Synovics Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Synovics Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR